Axsome Therapeutics, Inc. (AXSM)

Market Cap	4.32B
Revenue (ttm)	291.49M
Net Income (ttm)	-308.55M
Shares Out	48.00M
EPS (ttm)	-6.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	627,749
Open	91.25
Previous Close	90.70
Day's Range	89.13 - 91.37
52-Week Range	55.02 - 98.40
Beta	1.25
Analysts	Strong Buy
Price Target	124.64 (+38.38%)
Earnings Date	Nov 12, 2024

About AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 19, 2015
• Employees: 545
• Stock Exchange: NASDAQ
• Ticker Symbol: AXSM
• Website: https://www.axsome.com

Financial Performance

In 2023, Axsome Therapeutics's revenue was $270.60 million, an increase of 440.80% compared to the previous year's $50.04 million. Losses were -$239.24 million, 27.8% more than in 2022.

Analyst Forecast

According to 14 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price forecast is $124.64, which is an increase of 38.38% from the latest price.

Price Target

$124.64

(38.38% upside)

Analyst Consensus: Strong Buy